VectivBio Holding AG (VECT)
| Market Cap | 824.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.94M |
| Shares Out | 34.01M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 9 |
| Last Price | $24.23 |
| IPO Price | $17.00 |
| Change ($) | 7.23 |
| Change (%) | 42.53% |
| Day's Open | - |
| Day's Range | 19.32 - 37.47 |
| Day's Volume | - |
| 52-Week Range | 0.00 - 37.47 |
VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical...
VectivBio Holding, a Swiss Phase 3 biotech developing therapies for rare gastrointestinal disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
VectivBio Holding AG has filed to go public with an IPO on the NASDAQ.
About VECT
VectivBio Holding is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Our goal is to become a leading, patient-centric, fully integrated global rare disease company. Our current product pipeline is focused on rare gastrointestinal, or GI, disorders, and we intend to in-license or acquire additional transformational, differentiated rare disease assets. Our product candidate, apraglutide, i... [Read more...]
| Stock Exchange NASDAQ | Ticker Symbol VECT |